Retro-PROFIT; PReservation Of female Fertility In oncologic Treatment Fertility, pregnancy and quality of life after fertility-sparing treatment for gynaecological cancer.
Recruiting
- Conditions
- cervical cancerendometrial cancergynaecological cancerovarian cancer100385941001027310013356
- Registration Number
- NL-OMON53845
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1030
Inclusion Criteria
- Women with cervical, ovarian or endometrial cancer
- Age between 18-39 at time of diagnosis
- Fertility-sparing treatment between 2000 and 2020
Exclusion Criteria
For the questionnaire and interviewstudy:
- Living abroad and untraceable at time of data collection
- Deceased at time of data collection
- Insufficient understanding of the Dutch language
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Q1: 2-year and 5-year recurrence free survival<br /><br><br /><br>Q2:Percentage of women trying to conceive, within this group: pregnancy rate<br /><br>(number of first pregnancies after treatment divided by the number of women who<br /><br>tried to conceive) and number of pregnant women divided by the number of women<br /><br>who tried to conceive after treatment.<br /><br>Live birth rate<br /><br><br /><br>Q3:Initiation of pursuing pregnancy<br /><br>Psychological outcome: reproductive concerns, anxiety and depression, cancer<br /><br>worries and decisional regret. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Q1: 2- and 5-year survival and overall survival Q2:Type of conception<br /><br>(artificial or spontaneous) Miscarriages, gestational age at delivery (preterm<br /><br><28 weeks, preterm 28-32 weeks, preterm 32-37 weeks, term), mode of delivery<br /><br>(induction, caesarean section, spontaneous labor)</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fertility preservation in gynaecological cancer patients undergoing fertility-sparing treatments?
How does fertility-sparing treatment in cervical cancer compare to standard-of-care in terms of long-term reproductive outcomes and recurrence rates?
Which biomarkers are associated with successful pregnancy outcomes following fertility-sparing interventions in endometrial or ovarian cancer patients?
What are the potential adverse events linked to fertility-sparing approaches in young gynaecological cancer patients, and how are they managed?
Are there combination therapies or emerging drugs that enhance fertility preservation efficacy in gynaecological oncology alongside observational studies like NL-OMON53845?